ImpediMed Limited is thrilled to announce a major milestone in its journey to revolutionize patient care with the successful closing of a US$15,000,000 funding round. As the world leader in developing and distributing medical devices that utilize bioimpedance spectroscopy (BIS) technologies, ImpediMed continues to set industry benchmarks in noninvasive clinical assessment and monitoring of fluid status. This remarkable infusion of capital will further enhance our capabilities in research and innovation, allowing us to expand the reach and effectiveness of our groundbreaking product range. These devices play a crucial role in aiding surgeons, oncologists, therapists, and radiation oncologists as they assess and monitor patients for the onset of secondary lymphoedema. Early pre-operative clinical assessments in cancer survivors, conducted before the emergence of symptoms, are vital in preventing a lifelong condition that can adversely impact quality of life.
Having achieved the significant milestone of being the first to secure FDA clearance for a medical device that assists in the clinical assessment of secondary lymphoedema in both arms and legs of cancer patients, this new round of funding underscores the trust and confidence the market has in our innovative solutions. The raised funds will be strategically invested in accelerating product development, enhancing clinical research, and broadening our global distribution network. Ultimately, our goal is to improve patient outcomes and elevate the standard of care provided to cancer survivors worldwide, ensuring that early intervention becomes a standard practice in preventing secondary lymphoedema. As we embark on this exciting new phase, ImpediMed remains committed to advancing healthcare, empowering clinicians, and most importantly, enhancing the quality of life for patients everywhere.
